<DOC>
	<DOCNO>NCT01963611</DOCNO>
	<brief_summary>This Phase 2 , randomize , rater-blinded , 5-arm , parallel-group trial test 4 dos plovamer acetate active comparator Copaxone subject Relapsing Remitting Multiple Sclerosis ( RRMS ) . The trial conduct outpatient basis minimum treatment duration 40 week .</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability Plovamer Acetate ( Pathway 1 )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>Male female , age 18 60 year Subject able learn selfadminister subcutaneous injection ( caregiver may train inject subject ) Subjects must current diagnosis Relapsing Remitting Multiple Sclerosis ( RRMS ) ( accord 2010 McDonald MS diagnostic criterion ) Other protocol define inclusion criterion could apply Any multiple sclerosis categorize primary progressive , secondary progressive progressive relapse Allergy mannitol , plovamer acetate , Copaxone ( glatiramer acetate ) , Gd contrast MRI Any requirement continuous systemic glucocorticoid administration trial period . ( Note : Treatment interferon Avonex® , Rebif® , Betaseron® allow baseline visit , washout period need ) Contraindication Copaxone use Other protocol define exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Relapsing Remitting</keyword>
	<keyword>Plovamer acetate</keyword>
	<keyword>Copaxone</keyword>
</DOC>